FRAMINGHAM (03/22/2004) - Chemogenomic pioneer Iconix Pharmaceuticals Inc. recently got a big boost from major deals with Abbott Laboratories Inc. and Bristol-Myers Squibb Co. (BMS). "These are both very large platform relationships," says Alan Roter, Iconix's vice president of informatics. Financial terms for the arrangement with Abbott were not disclosed, but Iconix stands to earn approximately US$24 million from its multi-year deal with BMS alone.
Stories by Malorye A. Branca
FRAMINGHAM (03/10/2004) - Some speakers offered glimpses into the distant future, but most of the attendees at this year's AccelrysWorld, held March 8-10 in San Diego, were focused on today's pressing issues. "Data integration is still what interests me most," says attendee Mike Tennant of Trilogy Pharmaceuticals Inc., who spoke to Bio-IT World remotely from the meeting. "I spend a lot of my time investigating new database and software tools."
New CEO James Schoeneck sees his appointment this week as “the next stage of evolution for ActivX (Biosciences Inc.), in going from research to projects that will produce actual drugs.”
FRAMINGHAM (10/21/2003) - After two years of discussions, General Electric Co. (GE) acquired Amersham Biosciences in a whopping US$9.5 billion deal announced Oct. 10. The new combined business, GE Healthcare Technologies, will be led by Amersham's Chief Executive Officer, Sir William Castell. Recently, Andrew Carr, president of Discovery Systems at Amersham Biosciences, discussed the deal and the two-companies' shared vision, with Bio-IT World reporter Malorye A. Branca.